| The long noncoding RNA HORAS5 mediates castration‐resistant prostate cancer survival by activating the androgen receptor transcriptional program A Parolia, E Venalainen, H Xue, R Mather, D Lin, R Wu, P Pucci, ... Molecular oncology 13 (5), 1121-1136, 2019 | 30 | 2019 |
| Hypoxia and noncoding RNAs in taxane resistance P Pucci, P Rescigno, S Sumanasuriya, J de Bono, F Crea Trends in Pharmacological Sciences 39 (8), 695-709, 2018 | 30 | 2018 |
| The evolutionarily conserved long non‐coding RNA LINC00261 drives neuroendocrine prostate cancer proliferation and metastasis via distinct nuclear and … RL Mather, A Parolia, SE Carson, E Venalainen, D Roig‐Carles, M Jaber, ... Molecular oncology 15 (7), 1921-1941, 2021 | 23 | 2021 |
| LncRNA HORAS5 promotes taxane resistance in castration-resistant prostate cancer via a BCL2A1-dependent mechanism P Pucci, E Venalainen, I Alborelli, L Quagliata, C Hawkes, R Mather, ... Epigenomics 12 (13), 1123-1138, 2020 | 20 | 2020 |
| T‐type calcium channels drive the proliferation of androgen‐receptor negative prostate cancer cells R Silvestri, P Pucci, E Venalainen, C Matheou, R Mather, S Chandler, ... The Prostate 79 (13), 1580-1586, 2019 | 16 | 2019 |
| The role of autophagy and lncRNAs in the maintenance of cancer stem cells L Jahangiri, T Ishola, P Pucci, RM Trigg, J Pereira, JA Williams, ... Cancers 13 (6), 1239, 2021 | 14 | 2021 |
| HAR1: an insight into lncRNA genetic evolution E Waters, P Pucci, M Hirst, S Chapman, Y Wang, F Crea, CJ Heath Epigenomics 13 (22), 1831-1843, 2021 | 13 | 2021 |
| The contribution of autophagy and LncRNAs to MYC-driven gene regulatory networks in cancers L Jahangiri, P Pucci, T Ishola, RM Trigg, JA Williams, J Pereira, ... International journal of molecular sciences 22 (16), 8527, 2021 | 12 | 2021 |
| Mesothelin promoter variants are associated with increased soluble mesothelin-related peptide levels in asbestos-exposed individuals C De Santi, P Pucci, A Bonotti, O Melaiu, M Cipollini, R Silvestri, ... Occupational and Environmental Medicine 74 (6), 457-464, 2017 | 9 | 2017 |
| Deep analysis of neuroblastoma core regulatory circuitries using online databases and integrated bioinformatics shows their pan-cancer roles as prognostic predictors L Jahangiri, P Pucci, T Ishola, J Pereira, ML Cavanagh, SD Turner Discover Oncology 12 (1), 56, 2021 | 8 | 2021 |
| Combination therapy and noncoding RNAs: A new era of cancer personalized medicine P Pucci Epigenomics 14 (3), 117-120, 2022 | 6 | 2022 |
| The role of histone lysine demethylases in cancer cells’ resistance to tyrosine kinase inhibitors JC White, P Pucci, F Crea Cancer Drug Resistance 2 (2), 326, 2019 | 4 | 2019 |
| Brg1 and npm-alk are co-regulated in anaplastic large-cell lymphoma; brg1 is a potential therapeutic target in alcl GD Garland, SP Ducray, L Jahangiri, P Pucci, GA Amos Burke, ... Cancers 14 (1), 151, 2021 | 3 | 2021 |
| Variation rs2235503 C > A Within the Promoter of MSLN Affects Transcriptional Rate of Mesothelin and Plasmatic Levels of the Soluble Mesothelin-Related Peptide R Silvestri, P Pucci, C De Santi, I Dell’Anno, S Miglietta, A Corrado, ... Frontiers in Genetics 11, 975, 2020 | 2 | 2020 |
| HORAS5 promotes cabazitaxel resistance in castration resistant prostate cancer via a BCL2A1-dependent survival mechanism P Pucci, E Venalainen, I Alborelli, L Quagliata, R Mather, S Rigas, ... Annals of Oncology 30, v798, 2019 | 2 | 2019 |
| Long non-coding RNAs and cancer cells’ drug resistance: an unexpected connection P Pucci, W Yuen, E Venalainen, DR Carles, Y Wang, F Crea The Chemical Biology of Long Noncoding RNAs, 167-198, 2020 | 1 | 2020 |
| Targeting NRAS via miR-1304-5p or farnesyltransferase inhibition confers sensitivity to ALK inhibitors in ALK-mutant neuroblastoma P Pucci, LC Lee, M Han, JD Matthews, L Jahangiri, M Schlederer, ... Nature Communications 15 (1), 3422, 2024 | | 2024 |
| RESISTANCE TO ALK TYROSINE KINASE INHIBITORS IN PAEDIATRIC CANCER IS MEDIATED THROUGH ACTIVATION OF BYPASS SIGNALLING TRACKS INCLUDING IL10R/STAT3, RAS/MAP KINASE AND FGFR P Pucci, L Hare, J Matthews, N Prokoph, A Burke, S Turner PEDIATRIC BLOOD & CANCER 70, 2023 | | 2023 |
| WHAT IS THE BEST WAY TO ADMINISTER TARGETED THERAPEUTIC AGENTS TO INDUCE REMISSION AND PREVENT RESISTANCE FROM DEVELOPING? L Hare, P Pucci, J Matthews, A Burke, S Turner PEDIATRIC BLOOD & CANCER 70, 2023 | | 2023 |
| METTL3/MYCN cooperation drives neural crest differentiation and provides therapeutic vulnerability in neuroblastoma K Thombare, R Vaid, P Pucci, A Mendez, R Burgos-Panadero, ... bioRxiv, 2023.10. 06.561194, 2023 | | 2023 |
Crea FrancescoProfessor of Cancer Pharmacology, The Open UniversityVerified email at open.ac.uk
